Pharmaniaga Berhad Statistics
Total Valuation
KLSE:PHARMA has a market cap or net worth of MYR 353.10 million. The enterprise value is 1.39 billion.
Market Cap | 353.10M |
Enterprise Value | 1.39B |
Important Dates
The last earnings date was Monday, May 19, 2025.
Earnings Date | May 19, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
KLSE:PHARMA has 1.44 billion shares outstanding. The number of shares has increased by 2.92% in one year.
Current Share Class | 1.44B |
Shares Outstanding | 1.44B |
Shares Change (YoY) | +2.92% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 5.05% |
Owned by Institutions (%) | 8.98% |
Float | 477.28M |
Valuation Ratios
The trailing PE ratio is 2.60 and the forward PE ratio is 7.21.
PE Ratio | 2.60 |
Forward PE | 7.21 |
PS Ratio | 0.09 |
PB Ratio | -2.96 |
P/TBV Ratio | n/a |
P/FCF Ratio | 3.82 |
P/OCF Ratio | 2.94 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.59, with an EV/FCF ratio of 15.07.
EV / Earnings | 10.27 |
EV / Sales | 0.36 |
EV / EBITDA | 4.59 |
EV / EBIT | 5.24 |
EV / FCF | 15.07 |
Financial Position
The company has a current ratio of 0.65
Current Ratio | 0.65 |
Quick Ratio | 0.37 |
Debt / Equity | n/a |
Debt / EBITDA | 3.80 |
Debt / FCF | 12.48 |
Interest Coverage | 3.70 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | 7.91% |
Return on Invested Capital (ROIC) | 16.59% |
Return on Capital Employed (ROCE) | 764.18% |
Revenue Per Employee | 1.10M |
Profits Per Employee | 38,765 |
Employee Count | 3,502 |
Asset Turnover | 1.83 |
Inventory Turnover | 5.83 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.21% in the last 52 weeks. The beta is 1.18, so KLSE:PHARMA's price volatility has been higher than the market average.
Beta (5Y) | 1.18 |
52-Week Price Change | -34.21% |
50-Day Moving Average | 0.25 |
200-Day Moving Average | 0.33 |
Relative Strength Index (RSI) | 42.60 |
Average Volume (20 Days) | 3,852,510 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:PHARMA had revenue of MYR 3.85 billion and earned 135.76 million in profits. Earnings per share was 0.09.
Revenue | 3.85B |
Gross Profit | 543.79M |
Operating Income | 265.92M |
Pretax Income | 200.64M |
Net Income | 135.76M |
EBITDA | 292.94M |
EBIT | 265.92M |
Earnings Per Share (EPS) | 0.09 |
Balance Sheet
The company has 138.19 million in cash and 1.15 billion in debt, giving a net cash position of -1.02 billion or -0.70 per share.
Cash & Cash Equivalents | 138.19M |
Total Debt | 1.15B |
Net Cash | -1.02B |
Net Cash Per Share | -0.70 |
Equity (Book Value) | -119.09M |
Book Value Per Share | -0.10 |
Working Capital | -746.65M |
Cash Flow
In the last 12 months, operating cash flow was 120.26 million and capital expenditures -27.75 million, giving a free cash flow of 92.51 million.
Operating Cash Flow | 120.26M |
Capital Expenditures | -27.75M |
Free Cash Flow | 92.51M |
FCF Per Share | 0.06 |
Margins
Gross margin is 14.13%, with operating and profit margins of 6.91% and 3.53%.
Gross Margin | 14.13% |
Operating Margin | 6.91% |
Pretax Margin | 5.21% |
Profit Margin | 3.53% |
EBITDA Margin | 7.61% |
EBIT Margin | 6.91% |
FCF Margin | 2.40% |
Dividends & Yields
KLSE:PHARMA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.92% |
Shareholder Yield | n/a |
Earnings Yield | 38.45% |
FCF Yield | 26.20% |
Stock Splits
The last stock split was on July 5, 2021. It was a forward split with a ratio of 5.
Last Split Date | Jul 5, 2021 |
Split Type | Forward |
Split Ratio | 5 |
Scores
KLSE:PHARMA has an Altman Z-Score of 1.64. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.64 |
Piotroski F-Score | n/a |